VistaGen Therapeutics (NASDAQ:VTGN) Sign Agreement With Nuformix To Develop AV-101 cocrystalline Formulation For Various CNS conditions

VistaGen Therapeutics (NASDAQ:VTGN) has announced an agreement with Nuformix Plc to develop a cocrystalline formulation of AV-101 based ion VistaGen’s CNS products for the treatment of various CNS conditions.

VistaGen collaborates with Nuformix on AV-101 formulation

According to the terms of the agreement, the companies will at first use Nuformix’s novel technology in developing new patentable AV-101 crystalline forms that are likely to have enhanced therapeutic profile, superior delivery, and more intellectual property protection. If the first part is successful, the companies will consider extending opportunities to collaborate with other CNS therapeutic candidates to unlock more therapeutic and commercial opportunities.

VistaGen Chief Scientific Officer and President Ralph Snodgrass said that they are looking forward to having to work together with Nuformix, which has a highly experienced as well scientifically creative team. Snodgrass said that Nuformix has been successful in utilizing the cocrystal tech in the re-engineering of crystalline formulations of small molecule drugs for its development as well as for other partners.

Dan Gooding, the CEO of Nuformix, stated that he was delighted that the company was partnering with VistaGen and the chance to work on CNS therapeutics. Gooding added that they are looking forward to contributing significantly to the comprehensive AV-101 program of VistaGen and further enhancing collaboration.

AV-101 in combination with probenecid showing potential

The AV-101 program is an oral NMDAR glycine site antagonist from VistaGen being developed in combination with probenecid. Probenecid is a popular and safe oral drug used in gout and increasing therapeutic benefits of various anticancer, antiviral, and antibacterial drugs. Recent clinical data indicated a significant increase in brain concentration of 4-Cl-KYN (AV-101 prodrug) and the active metabolite 7-Cl-KYNA when given in combination with probenecid.

With an excellent safety profile and few side effects in clinical studies, the combination of AV-101 and probenecid has shown potential as a treatment for epilepsy, chronic neuropathic pain, Parkinson’s disease therapy-related levodopa-induced dyskinesia, suicidal ideation, and major depressive disorder.